IDXX vs. MCO, NVST, ZTS, ISRG, BSX, SYK, MDT, BDX, EW, and RMD
Should you be buying IDEXX Laboratories stock or one of its competitors? The main competitors of IDEXX Laboratories include Moody's (MCO), Envista (NVST), Zoetis (ZTS), Intuitive Surgical (ISRG), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), and ResMed (RMD).
IDEXX Laboratories vs. Its Competitors
Moody's (NYSE:MCO) and IDEXX Laboratories (NASDAQ:IDXX) are related large-cap companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.
Moody's has a net margin of 29.18% compared to IDEXX Laboratories' net margin of 24.41%. IDEXX Laboratories' return on equity of 64.42% beat Moody's' return on equity.
Moody's currently has a consensus price target of $538.80, indicating a potential upside of 4.06%. IDEXX Laboratories has a consensus price target of $623.56, indicating a potential downside of 0.10%. Given Moody's' higher probable upside, analysts clearly believe Moody's is more favorable than IDEXX Laboratories.
In the previous week, IDEXX Laboratories had 33 more articles in the media than Moody's. MarketBeat recorded 70 mentions for IDEXX Laboratories and 37 mentions for Moody's. Moody's' average media sentiment score of 1.14 beat IDEXX Laboratories' score of 1.07 indicating that Moody's is being referred to more favorably in the media.
Moody's has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.
Moody's has higher revenue and earnings than IDEXX Laboratories. Moody's is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
92.1% of Moody's shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 0.1% of Moody's shares are owned by company insiders. Comparatively, 1.0% of IDEXX Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Moody's beats IDEXX Laboratories on 9 of the 17 factors compared between the two stocks.
Get IDEXX Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
IDEXX Laboratories Competitors List
Related Companies and Tools
This page (NASDAQ:IDXX) was last updated on 8/7/2025 by MarketBeat.com Staff